HB-EGF is produced in the peritoneal cavity and enhances mesothelial cell adhesion and migration

Kidney International

Volumn 59, Issue 2, 2001, Pages 614-624

  Faull, Randall J ^a,b   Stanley, Jodie M ^b,c   Fraser, Scott ^c   Power, David A ^c   Leavesley, David I ^c  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c NONE

Author keywords

CAPD; Fibrogenesis; Inflammation; Peritonitis; Toxic dialysate; Ultrafiltration; Wound repair

Indexed keywords

CD9 ANTIGEN; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; HERMES ANTIGEN; INTEGRIN; RECEPTOR;

ARTICLE; CELL ADHESION; CELL MIGRATION; CHEMOTAXIS; CONFOCAL MICROSCOPY; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MESOTHELIUM CELL; NUCLEOTIDE SEQUENCE; PERITONEAL CAVITY; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WOUND HEALING;

EID: 0035138913     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2001.059002614.x     Document Type: Article

References (44)

1. Peritoneal dialysis solution biocompatibility: Inhibitory mechanisms and recent studies with bicarbonate-buffered solutions
2. Cytotoxic effects of commercial CAPD fluids and of bacterial exoproducts oil human mesothelial cells in vitro
3. Membrane longevity in peritoneal dialysis: Impact of infection and bio-incompatible solutions
4. Epidermal growth factor modifies the expression and function of extracellular matrix adhesion receptors expressed by peritoneal mesothelial cells from patients on CAPD
5. The mesothelial cells in CAPD effluent and their relation to peritonitis incidence
6. Peritoneal morphology on maintenance dialysis
7. Categorization of ultrastructural changes in peritoneal mesothelium, stroma and blood vessels in uremia and CAPD patients
8. Wound healing: Aiming for perfect skin regeneration
9. Growth factors and cutaneous wound repair
10. Host defense mechanisms in the peritoneal cavity of continuous ambulatory peritoneal dialysis patients
11. Activation of immunocompetent cells in the peritoneum of patients treated with CAPD
12. Presence of different mitogenic activities in the nocturnal peritoneal effluent of patients treated with CAPD
13. Transforming growth factor beta and the pathogenesis of glomerular diseases
14. Transforming growth factor beta in tissue fibrosis
15. The role of growth factors in peritoneal healing: Transforming growth factor β (TGF-β)
16. Enhanced expression of TGF-β by peritoneal macrophages in CAPD patients
17. Persistent transforming growth factor-beta 1 expression may predict peritoneal fibrosis in CAPD patients with frequent peritonitis occurrence
18. Transforming growth factor-β synthesis by human peritoneal mesothelial cells: Induction by interleukin- 1
19. High glucose solution and spent dialysate stimulate the synthesis of transforming growth factor-β1 of human peritoneal mesothelial cells: Effect of cytokine costimulation
20. Interleukin-1β stimulates the production of extracellular matrix in cultured human peritoneal mesothelial cells
21. Effect of glucose on TGF-β 1 expression in peritoneal mesothelial cells
22. Transforming growth factor-β stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix
23. New concepts in molecular biology and ultrastructural pathology of the peritoneum: Their significance for peritoneal dialysis
24. Effects of glucose and TGF-β 1 on the proliferation of cultured human peritoneal mesothelial cells
25. PAI-1 secretion and matrix deposition in human peritoneal mesothelial cell cultures: Transcriptional regulation by TGF-β 1
26. Modulation of pro- and antifibrinolytic properties of human peritoneal mesothelial cells by transforming growth factor-β1 (TGF-β1), tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β)
27. Isolation, culture and characterization of human peritoneal mesothelial cells
28. 2 production by human peritoneal macrophages
29. Inhibition of heparin-binding epidermal growth factor-like growth factor (HB-EGF) increases albuminuria in puromycin aminoglycoside nephrosis
30. Contributing software to the internet: The Amplify program
31. Affinity modulation of integrin α5β1: Regulation of the functional response by soluble fibronectin
32. Heparin-binding EGF-like growth factor
33. Expression cloning of a diphtheria toxin receptor: Identity with a heparin-binding EGF-like growth factor precursor
34. Membrane-anchored heparin-binding EGF-like growth factor (HB-EGF) and diphtheria toxin receptor-associated protein (DRAP27)/CD9 form a complex with integrin α3β1 at cell-cell contact sites
35. The tetraspanin superfamily: Molecular facilitators
36. Heparin-binding EGF-like growth factor, which acts as the diphtheria toxin receptor, forms a complex with membrane protein DRAP27/CD9, which up-regulates functional receptors and diphtheria toxin sensitivity
37. CD9 antigen interacts with heparin-binding EGF-like growth factor through its heparin-binding domain
38. CD44 isoforms containing exon V3 are responsible for the presentation of heparin-binding growth factor
39. Activation of HER4 by heparin-binding EGF-like growth factor stimulates chemotaxis but not proliferation
40. Appearance of heparin-binding EGF-like growth factor in wound fluid as a response to injury
41. High glucose and hyperosmolarity increase heparin-binding epidermal growth factor-like growth factor (HB-EGF) production in cultured human aortic endothelial cells
42. Coexpression of CD9 augments the ability of membrane-bound heparin-binding epidermal growth factor-like growth factor (proHB-EGF) to preserve renal epithelial cell viability
43. Alterations of integrins by heparin-binding EGF-like growth factor in human breast cancer cells
44. Response of the human mesothelial cell to injury: An in vitro model of peritoneal wound healing